Efficacy of tyrosine kinase inhibitors in patients with non-small-cell lung cancer with performance status 4: A case series and review of the literature

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

13 p | 10 | 2

Influence of cytochrome P450 and glutathione S transferase polymorphisms on response to nilotinib therapy among chronic myeloidleukemia patients from Pakistan

11 p | 4 | 2

Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: A real-world study

10 p | 1 | 1

Clinical impact of tetracyclines and/ or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: A retrospective cohort study

12 p | 1 | 1

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

8 p | 8 | 1

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

9 p | 10 | 1

Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: An open-label phase 1b study

9 p | 11 | 1

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

10 p | 7 | 1

Comparison of the efficacies of firstgeneration epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced nonsmall-cell lung cancer harboring EGFR mutations

7 p | 5 | 0